| __timestamp | MorphoSys AG | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 77000 | 22622695 |
| Thursday, January 1, 2015 | 77000 | 24863028 |
| Friday, January 1, 2016 | 97000 | 21351001 |
| Sunday, January 1, 2017 | 33000 | 53837297 |
| Monday, January 1, 2018 | 1796629 | 16080096 |
| Tuesday, January 1, 2019 | 12085198 | 18525736 |
| Wednesday, January 1, 2020 | 9174146 | 2024000 |
| Friday, January 1, 2021 | 32200000 | 2548000 |
| Saturday, January 1, 2022 | 48620000 | 61556000 |
| Sunday, January 1, 2023 | 58355000 | 188157000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biopharmaceuticals, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for Telix Pharmaceuticals Limited and MorphoSys AG from 2014 to 2023. Over this period, Telix Pharmaceuticals has seen a staggering increase in its cost of revenue, peaking at approximately 188 million in 2023, a remarkable 730% rise from its 2014 figures. In contrast, MorphoSys AG's cost of revenue has grown more steadily, reaching around 58 million in 2023, marking a significant 75,000% increase from its modest 33,000 in 2017. This data highlights the contrasting growth trajectories and financial strategies of these two industry players. As the biopharma sector continues to expand, these insights offer a glimpse into the financial underpinnings that drive innovation and market leadership.
Cost of Revenue: Key Insights for Johnson & Johnson and MorphoSys AG
Cost Insights: Breaking Down Sanofi and MorphoSys AG's Expenses
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: BeiGene, Ltd. vs MorphoSys AG
Analyzing Cost of Revenue: United Therapeutics Corporation and MorphoSys AG
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Alkermes plc
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Perrigo Company plc's Expenses
CRISPR Therapeutics AG vs MorphoSys AG: Efficiency in Cost of Revenue Explored
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: MorphoSys AG and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: MorphoSys AG vs Evotec SE